

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, C12N 5/00, C12Q 1/02, 1/68	A1	(11) International Publication Number: WO 97/02049 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/US96/11304 (22) International Filing Date: 5 July 1996 (05.07.96) (30) Priority Data: 08/499,093 6 July 1995 (06.07.95) US (71) Applicant: EMORY UNIVERSITY [US/US]; 2009 Ridgewood Drive, Atlanta, GA 30322 (US). (72) Inventor: LUSKIN, Maria, B.; 1469 Hampton Glen Court, Decatur, GA 30033 (US). (74) Agents: SELBY, Elizabeth et al.; Needle & Rosenberg, Suite 1200, 127 Peachtree Street, N.E., Atlanta, GA 30303 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: NEURONAL PROGENITOR CELLS AND USES THEREOF (57) Abstract The present invention provides an isolated cellular composition comprising greater than about 90 % mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Also provided are methods of treating neuronal disorders utilizing this cellular composition.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NEURONAL PROGENITOR CELLS AND USES THEREOF

This invention was made with government support under NIH grant number NS 28380 awarded by the National Institutes of Health. The government has certain rights
5 in the invention.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to an isolated cellular composition comprising a
10 substantially homogeneous population of mammalian neuronal progenitor cells.
Additionally, the present invention relates to methods of delivering biologically active
molecules to a mammalian brain by transplanting the cellular composition to the brain.

Background Art

15 Because mammalian neurons are generally incapable of dividing when mature,
sources of dividing neuronal cells have been sought. Several difficulties have arisen,
however, in identifying sources of dividing cells that generate neurons because neuronal
progenitor cells frequently fail to express neuronal markers and because heterogeneous
populations of cells (including neuronal and non-neuronal cells) generally arise and often
20 individual progenitor cells can give rise to neurons and non-neuronal cells.

Neoplastic cell lines and immortalized neural precursors have been used to
provide relatively homogeneous populations of cells. Because these cells are rapidly
dividing, they generally show a limited ability to fully differentiate into cells with a
neuronal phenotype. For example, PC12 cells derived from a pheochromocytoma fail to
25 differentiate or maintain a differentiated state in culture in the absence of nerve growth
factor (NGF). (Green and Tischler, *Advances in Cellular Neurobiology*, S. Federoff and
L. Hertz, eds. (Academic Press, N.Y.), (1982). Additionally, these cells are tumor-
derived and have neoplastic characteristics. Furthermore, a number of immortalized
neural precursor cell lines generate a heterogeneous population of cells.

30 Similarly, embryonal carcinoma cell lines have been differentiated in culture
under special conditions. NT2 cells, derived from a teratocarcinoma, will give rise to

cells that differentiate in culture only following extended treatment of the parent cells with retinoic acid. The NT2 cells, however, differentiate into both neuronal and non-neuronal cell types. The resulting mixed culture must be treated with mitotic inhibitors and then the cells replated to remove the dividing non-neuronal cells and approach a
5 relatively pure population of neuronal cells. (U.S. Patent No. 5,175,103). These relatively pure neuronal cells nonetheless are tumor-derived and have neoplastic characteristics.

Sources of neuronal precursors from adult and neonatal mammalian nervous systems have generally resulted in similar problems with heterogeneity. Reynolds and
10 Weiss, *Science* 255:1707 (1992), have cultured cells from the adult striatum, presumably including portions of the subventricular zone. The cells were cultured in the presence of epidermal growth factor (EGF) and allowed to form large cell clusters, which were termed "neurospheres." The spheres were then dissociated and the cells were cultured in the presence of EGF. The resulting cell cultures consisted of a mixture of post-
15 mitotic neurons, glia, and subependymal cells. Thus, by these means, some of the newly-generated cells were induced to differentiate into neurons; however, the proportion of neurons obtained is low by this method. Others have been able to induce some neuronal proliferation from cultures of the neonatal telencephalon, by administration of fibroblast growth factor. Like the method of Reynolds and Weiss, this
20 neonatal source also results in low proportions of neurons compared to non-neuronal cells. Relatively pure populations of neuronal cells can be achieved by these methods only following treatment with mitotic inhibitors. Therefore, the relatively pure neuronal cells are post-mitotic.

The subventricular zone is known to be a source of certain dividing cells in the
25 nervous system. However, the subventricular zone has been viewed predominantly as a source of glia and not neurons (Paterson *et al.*, *J. Comp. Neurol.*, 149:83, 1973; LeVine and Goldman, *J. Neurosci.*, 8:3992, 1988; Levison and Goldman, *Neuron* 10:201 (1993). This was the consensus concerning the intact, *in vivo* subventricular zone. Luskin, however, (*Neuron*, 11:173 (1993)) found that a discrete region of the intact
30 subventricular zone produced numerous neurons that differentiated into olfactory bulb neurons *in vivo*. Nevertheless, other investigators who have cultured cells derived from

SUMMARY OF THE INVENTION

The present invention provides an isolated cellular composition comprising greater than about 90%, and preferably greater than about 95%, mammalian, non tumor-
5 derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells.

The instant invention additionally provides a method of delivering a biologically active molecule produced by the neuronal progenitor cells, or their progeny, or mixtures thereof, of a cellular composition comprising greater than about 90% mammalian, non
10 tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells to a region of a mammalian brain, comprising transplanting the cellular composition into the region of the brain, thereby delivering a biologically active molecule produced by the cells or their progeny to the region.

15 Additionally, the present invention provides a method of delivering a biologically active molecule produced by the neuronal progenitor cells, or their progeny, or mixtures thereof, of a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells and which are
20 transfected with an exogenous nucleic acid that functionally encodes a biologically active molecule to a region of a mammalian brain comprising transplanting the cellular composition into the region of the brain, thereby delivering the biologically active molecule produced by the cells or their progeny to the region.

The present invention further provides a method of treating a neuronal disorder
25 characterized by a reduction of catecholamines in the brain of a mammal, comprising transplanting into the brain a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells, or their progeny, or mixtures thereof, thereby providing a source of
30 catecholamines to the brain and treating the disorder.

Also provided by the present invention is a method of treating Alzheimer's disease in a subject comprising transplanting into the brain of the subject a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells and which are transfected with an exogenous nucleic acid that functionally encodes a biologically active molecule that stimulates cell division or differentiation, that promotes neuronal survival, or that functions in the synthesis of a neurotransmitter, or their progeny, or mixtures thereof, thereby treating Alzheimer's disease.

10 The present invention additionally provides a method of treating a neuronal disorder characterized by a reduction of γ -aminobutyric acid in the brain in a mammal, comprising transplanting into the brain a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells, or their progeny, or mixtures thereof, thereby providing a source of γ -aminobutyric acid to the brain and treating the disorder.

Also provided by the present invention is a method of screening for a marker of neuronal cells comprising obtaining the neuronal progenitor cells of a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells, and detecting the presence of a marker in the neuronal progenitor cells that is not present in non-neuronal cells, the marker present in the neuronal progenitor cells that is not present in the non-neuronal cells being a marker of neuronal cells.

25 The present invention also provides a method of detecting a neuronally expressed gene comprising obtaining a cDNA library from the neuronal progenitor cells of a cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells, obtaining a cDNA library from a non-neuronal cell, determining the presence at higher levels of a cDNA in the library from the neuronal progenitor cells than in the non-neuronal cell, the presence at

higher levels of a cDNA in the library from the neuronal progenitor cells indicating a neuronally expressed gene.

The present invention further provides a method of obtaining an isolated cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuronal marker and which can give rise to progeny which can differentiate into neuronal cells, comprising isolating cells from the portion of a mammalian brain that is the equivalent of the anterior portion of the subventricular zone at the dorsolateral portion of the anterior-most extent of the region surrounding the ventricle of a neonatal rat brain and culturing the isolated cells in the absence of mitotic inhibitors.

The instant invention also provides an isolated cellular composition comprising greater than about 50% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which give rise to progeny which can differentiate into neuronal cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the homotopic transplantation procedure. (A) shows the SVZa, situated between the antero-lateral portion of the lateral ventricle and the overlying corpus callosum, microdissected from a sagittally sectioned neonatal (P0 - P2) forebrain. (B) shows pieces of tissue containing the neuronal progenitor cells of the SVZa which were collected together, trypsinized, washed and mechanically dissociated by trituration into single cells or small clumps. (C) shows the cell suspension which was carefully washed, evaluated for viability, then labeled by the fluorescent, lipophilic dye PKH26 or BrdU to ensure the unequivocal identification of transplanted SVZa cells in the host brain. (D) shows the dissociated, PKH26-labeled SVZa cells stereotactically placed into the SVZa of a host brain.

Figure 2 shows the heterotopic transplantation procedure for transplanting P0-P2 SVZa neuronal progenitor cells into the neonatal striatum. (A) shows a representative drawing of a parasagittal section of the neonatal rat forebrain showing the location of the SVZa (black area). The SVZa was microdissected from the P0-P2 rat forebrain using a microknife. (B) shows the individual tissue pieces collected in an

Eppendorf tube and dissociated using fire polished Pasteur pipettes to obtain a single cell suspension of SVZa cells. (C) shows the SVZa cell suspension labeled with PKH26, a lipophilic red fluorescent dye. (To label the SVZa cells with the cell proliferation marker, BrdU, P0-P2 pups were injected intraperitoneally with BrdU. A day later the SVZa was dissected and dissociated into a cell suspension). (D) shows the labeled SVZa cell suspension stereotactically implanted into the striatum (ST) at P0-P2. CC, corpus callosum; CTX, cerebral cortex; D, dorsal; LV, lateral ventricle; OB, olfactory bulb; P, posterior. Scale bar in (A) = 2 mm and also applies to (D).

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following detailed description of specific embodiments and the Examples included therein.

15 The present invention provides an isolated cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Preferably at least about 95%, and more preferably greater than about 98%, of the composition is mammalian, non-tumor-derived, neuronal
20 progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. By "isolated," as used in the claims, is meant removed from the mammalian brain. As described herein, a region of the anterior subventricular zone (SVZa) isolated from a mammalian brain is shown herein to provide a cellular composition of greater than about 90% neuronal progenitor cells
25 which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Compositions can also be obtained having, for example, about 50, 60, 70, 80 or 85% neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Preferably, greater than about 95%, or even more preferably, greater than about 98%, of
30 the cells in the composition are neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal

cells. Particularly at the time of isolation, about 98 to 100% of the cells in the composition can be neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Thus, the invention provides a substantially homogeneous composition of neuronal progenitor
5 cells.

As used herein, "neuronal cells" or "neurons" includes cells which are post-mitotic and which express one or more neuron-specific markers. Examples of such markers can include but are not limited to neurofilament, microtubule-associated protein-2, and tau, and preferably neuron-specific Class III β -tubulin and neu N. As used herein "neuronal
10 progenitor cells" are cells which can give rise to progeny which can differentiate into neuronal cells, but, unlike neuronal cells, are capable of cell division *in vivo* or *in vitro*, and which also, like post-mitotic neurons, express a neuron-specific marker.

In these compositions, preferably only about 10%, or more preferably about 5%, or even more preferably about 2%, or fewer of the cells in the composition are non-
15 neuronal cells. Non-neuronal cells include cells which express a glia-specific marker, such as glial fibrillary acidic protein (GFAP), or which do not express any neuron-specific markers. Non-neuronal cells can include but are not limited to glial cells, subependymal cells, microglia and fibroblasts and do not include neuronal progenitor cells.

20 As used herein, the "progeny" of a cell can include any subsequent generation of the cell. Thus, the progeny of a neuronal progenitor cell can include, for example, a later generation neuronal progenitor cell, a later generation cell that has undergone differentiation, or a fully differentiated, post-mitotic neuronal cell.

It must be noted that, as used in the specification and the appended claims, the
25 singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.

The present invention provides a cellular composition comprising mammalian, non-tumor derived cells which express a neuron-specific marker and which can divide. The cellular composition can be isolated from the region corresponding to the anterior
30 portion of the subventricular zone (termed "SVZa" interchangeably herein) region of rat brain as described further herein and exemplified in the Examples below. The

substantially homogeneous composition can be obtained in the absence of treatment with mitotic inhibitors. In addition, the ability of the cells to divide can be achieved in the absence of immortalization techniques. The neuronal progenitor cells can, without being first immortalized, divide for at least two generations. At least about two, preferably at
5 least about five, and more preferably at least about ten or more generations of dividing neurons can result when the isolated cells are placed in standard culture conditions as exemplified in the Examples below.

Additionally, the cells of the substantially homogeneous composition of neuronal progenitor cells can give rise to progeny which can differentiate into neuronal cells. By
10 use of this composition, therefore, one can obtain, in the absence of mitotic inhibitors, a composition comprising greater than 90%, and preferably greater than 95%, and more preferably greater than 98%, of any of the following cells: neuronal progenitor cells, progeny of neuronal progenitor cells and neuronal cells.

The cells comprising the herein described composition can be isolated from the
15 SVZa of the brain of any mammal of interest. For example, cells can be obtained from mouse, rat, pig, monkey and human. Preferred sources can be postnatal rat, pig and mouse and prenatal monkey and human brain, though many other sources will be apparent to the practitioner. The SVZa in rat is the dorsolateral portion of the anterior-most extent of the subventricular zone surrounding the ventricles. It is anterior and
20 dorsal to the striatum. It has a different appearance and whiter coloration than the surrounding structures. In addition, it is more opaque than the overlying corpus callosum, presumably because of the density of cells in the region. In other mammals such as human, monkey and mouse, the corresponding region can be located by both this location within the brain and by these physical characteristics.

25 The present invention provides a cellular composition wherein at least a portion of the cells are transfected by a selected nucleic acid. The cells can be transfected with an exogenous nucleic acid as exemplified in the Examples below. "Exogenous" can include any nucleic acid not originally found in the cell, including a modified nucleic acid originally endogenous to the cell prior to modification. By "transfected" is meant to
30 include any means by which the nucleic acid can be transferred, such as by infection, transformation, transfection, electroporation, microinjection, calcium chloride

precipitation or liposome-mediated transfer. These transfer methods are, in general, standard in the art (*see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989)). Preferably at least about 3%, more preferably about 10%, more preferably
5 about 20%, more preferably about 30%, more preferably about 50%, and even more preferably about 75% of the cells, at least initially after the transfection procedure is performed, are successfully transfected. To increase the percentage of transfected cells, multiple transfections can be performed. For example, one can infect cells with a vector of choice, remove the media after infection, reinfect, etc. and repeat the process to
10 achieve the desired percentage of infected cells. Some viruses, for example, can be viable for about two hours at a 37°C incubation temperature; therefore, the infection can preferably be repeated every couple of hours to achieve higher percentages of transfected cells. Other methods of increasing transfected cell number, such as transient transfection (Pear, W.S. *et al., Proc. Natl. Acad. Sci. USA* 90:8392-8396 (1993)), are
15 known and standard in the art.

Any selected nucleic acid can be transferred into the cells. For example, a nucleic acid that functionally encodes a biologically active molecule can be transfected into the cells. Preferable nucleic acids can include, for example, nucleic acids that encode a biologically active molecule that stimulates cell division or differentiation or that
20 promotes neuronal survival such as, for example, growth factors, *e.g.,* nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-3 and NT-4/5, ciliary neurotrophic factor (CNTF), and factors that block growth inhibitors. Additionally, preferable nucleic acids can include nucleic acids that encode a biologically active molecule that functions in the synthesis of a neurotransmitter, such as tyrosine
25 hydroxylase (TH) and glutamic acid decarboxylase (GAD). The nucleic acid can be in any vector of choice, such as a plasmid or a viral vector, and the method of transfer into the cell can be chosen accordingly. As known in the art, nucleic acids can be modified for particular expression, such as by using a particular cell- or tissue-specific promoter, by using a promoter that can be readily induced, or by selecting a particularly strong
30 promoter, if desired.

The present invention also provides methods for isolating the cellular compositions. Thus, methods are provided for isolating a substantially homogeneous composition in the absence of special culture conditions or treatment with mitotic inhibitors and for transfecting at least a portion of the neuronal progenitor cells or their progeny with exogenous DNA. Specifically, the present invention provides a method of obtaining an isolated cellular composition wherein greater than about 90%, and preferably greater than about 95%, and even more preferably greater than about 98%, of the cells of the composition are non-tumor-derived, neuronal progenitor cells which express a neuronal marker and which can give rise to progeny which can differentiate into neuronal cells, comprising isolating cells from the anterior portion of the subventricular zone (SVZa) of a mammalian brain and culturing the cells in the absence of mitotic inhibitors. As discussed above, sources of such cells can preferably be postnatal rat, pig or mouse and prenatal monkey or human brain. The cells are isolated from the SVZa of the selected mammal, as described herein and exemplified in the Examples. The SVZa is located by both its location, as described and exemplified herein, and its physical characteristics, as described and exemplified herein. The cells can then be cultured in the absence of mitotic inhibitors. Thus, the cellular composition, as isolated, can be substantially devoid (*i.e.*, comprises less than 10%, preferably less than 5%, more preferably less than 2%) of glial and other non-neuronal cells, and thus culture conditions designed to eliminate non-neuronal cells from the compositions can often be omitted. Therefore, the cultured cells are not subjected, for example, to mitotic inhibitors. However, if desired, mitotic inhibitors can be utilized. Additionally, the isolated cells can be transfected with an exogenous nucleic acid so that at least a portion of the population is transfected. Furthermore, the cells of the isolated cellular composition can be immortalized by standard methods, such as transformation, to create a cell line (*see, e.g.*, Gage, F.H. *et al.*, *Annu. Rev. Neurosci.* 18:159 (1995)).

The present invention also provides methods for delivering biologically active molecules produced by the neuronal progenitor cells of the composition or their progeny into a region of the brain by transplantation of the cellular composition. Specifically, the present invention provides a method of delivering a biologically active molecule produced by the neuronal progenitor cells of the composition or their progeny or

mixtures thereof described above (which composition comprises an isolated cellular composition of mammalian, non-tumor-derived, neuronal progenitor cells of which greater than about 90%, preferably greater than about 95%, and preferably greater than about 98%, express a neuron-specific marker and can give rise to progeny which can
5 differentiate into neuronal cells) to a region of a mammalian brain comprising transplanting the cellular composition into the region of the brain, thereby delivering a biologically active molecule produced in the cells to the region. The neuronal progenitor cells of the composition or their progeny or mixtures thereof can be transplanted to a host brain, either without being previously cultured or following
10 culture. Culturing can preferably be performed according to standard conditions for neuronal cells or in defined medium with growth factors, as exemplified herein and known in the art. Cells can be cultured for any desirable length of time. For example, cells can be cultured for several days, which can expand the number of cells. For example, the neuronal progenitor cells can be allowed to divide at least once, more
15 preferably twice, five times or ten times or more prior to transplant. Additionally, the cells transplanted prior to differentiation can divide *in vivo* after transplantation. Furthermore, cells for transplantation can be transfected with an exogenous nucleic acid, and the cells can undergo several rounds of transfection with an exogenous nucleic acid prior to transplantation.

20 Transplantation can be performed for the purpose of delivering to the host brain biologically active molecules normally produced by the transplanted cells (*i.e.*, endogenously-encoded products) or for the purpose of delivering to the host brain biologically active molecules resulting from exogenously introduced DNA in transfected cells that are then transplanted. The term "biologically active molecules," as described
25 also above, includes but is not limited to synthetic enzymes, neurotransmitters, putative neurotransmitters, neurotrophic factors, and factors that can block inhibitors of cell division and/or differentiation.

Transplanting, as known in the art, can be, for example, a stereotaxic injection of a cell suspension, and this injection can be into either a homotopic or heterotopic brain
30 region. Transplantation can be performed as exemplified in the Examples herein. (Dunnett, S.B. and Björklund, A., eds., *Transplantation: Neural Transplantation-A*

Practical Approach, Oxford University Press, Oxford (1992)) Cells, for example, can be suspended in a buffer solution, or alternatively whole tissue comprising the cellular composition, can be transplanted. Dissociated cell suspensions can maximize cell dispersion and vascularization of the graft. Poor vascularization is a significant factor in poor graft survival. Cells can be labeled prior to transplant, if desired. Multiple transplants can be performed, depending upon the number of transplanted cells desired to be transplanted and the area of the target region that receives the transplanted cells. Transplanted cells can preferably divide *in vivo* after transplantation for a limited number of generations, to create a larger region of neuronal progenitor cells and larger numbers of the cells without generating tumor formation. Additionally, transplanted cells can preferably migrate or disperse somewhat within the brain and thus create a larger region receiving these cells. Furthermore, transplanted cells can preferably eventually differentiate into mature neurons.

The present invention provides a method of treating a variety of neuronal disorders or diseases which the provision of a biologically active molecule can treat. By "treating" is meant causing an improvement in any manifestation of the specific disorder or disease. The disorders include but are not limited to disorders characterized by a reduction of catecholamines (such as Parkinson's Disease), by a reduction of GABA (such as certain forms of epilepsy and Huntington's Disease), or by neurodegenerative conditions (such as Alzheimer's Disease). To treat the specific disorder/disease, transfected or non-transfected cells of the compositions or their progeny or mixtures thereof can be transplanted into the host brain wherein the host brain demonstrates the neuronal disorder. The transplantation provides to the brain biologically active molecules produced by the transplanted cells, whether the molecules are endogenous to the transplanted neuronal progenitor cells or their progeny or whether a nucleic acid encoding the molecules were transfected into the transplanted neuronal progenitor cells or their progeny prior to transplantation. Additionally, for example, the cells can be treated prior to transplantation in a manner to cause increased production of the biologically active molecule. Alternatively the cells can be used as a source of the appropriate growth factors to treat the disease. Relatedly, the cells can be used to

screen for novel growth factors which in turn could be screened for therapeutic potential.

Therefore, in one embodiment, cells can be selected for transplantation that will provide a specific biologically active molecule that will treat the specific disease of the subject. For example, for a subject having a disorder characterized by a reduction of catecholamines (such as Parkinson's Disease (PD)), the substantially homogeneous composition comprising isolated neuronal progenitor cells or their progeny, or mixtures thereof, as described above, can be transplanted, for example, for PD, into the region of the striatum. The transplanted cells need not have an exogenous nucleic acid transfected into them, as at least a portion of the cells can produce catecholamines, particularly dopamine. However, if desired, the cells can be transfected with an exogenous nucleic acid prior to transplantation. For example, recombinant nucleic acids encoding enzymes that produce higher than normal levels of the desired biologically active molecule can be utilized, if desired. Other desirable manipulation of the cells will be apparent to the practitioner, in light of the teachings herein.

Another example is treatment of a subject having a disorder characterized by a reduction of GABA, such as certain forms of epilepsy (*Merritt's Textbook of Neurology*, 9th ed. (L.P. Rowland, ed. Williams and Wilkins, Baltimore, 1995)), and Huntington's Disease (HD) (Martin, J.B. & Gusella, J.F. *Huntington's Disease: Pathogenesis and Management*, New Eng. J. Med. 315:1267-1276 (1986)). These subjects can be treated by transplanting into the brain (*e.g.*, into regions such as the cerebral cortex and striatum) cells of the composition or their progeny or mixture thereof as described herein. These cells need not have an exogenous nucleic acid transfected into them, since a substantial portion of the cells can produce GABA. However, if desired, the cells can be transfected with an exogenous nucleic acid. For example, recombinant nucleic acids encoding enzymes that produce higher than normal levels of the product can be utilized, if desired. Other desirable manipulation of the cells will be apparent to the practitioner, in light of the teachings herein. The cells can be transplanted, for example, into regions such as the hippocampus and/or the cerebral cortex, for epilepsy, and the striatum, for Huntington's Disease.

Another example for treatment is neurodegenerative conditions, for example, Alzheimer's Disease. (R.D. Terry, R. Katzman and K.L. Bick, *Alzheimer's Disease*,

Raven Press, NY (1994)). A cellular composition as described herein comprising cells into which has been transfected, for example, a nucleic acid encoding a biologically active molecule that stimulates cell division or differentiation or promotes neuronal survival (such as growth factors *e.g.*, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-3 and NT-4/5 and CNTF, or factors that block growth inhibitors), so as to decrease the amount of degeneration, can be transplanted into the brain of the subject (*e.g.*, into regions such as basal forebrain, hippocampus, and/or cerebral cortex). Other desirable manipulation of the cells will be apparent to the practitioner, in light of the teachings herein. The cells can also be used in conjunction with various growth factors for optimal therapeutic effect. Relatedly the cells can be administered with various growth factors to screen factors for therapeutic value in animal models.

The present invention also provides a method of screening for markers of neuronal cells. Specifically, the present invention provides a method of screening for a marker of neuronal cells comprising obtaining the cellular composition described herein (which composition comprises greater than about 90% or 95% or even 99% neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells), obtaining non-neuronal cells or information concerning the markers of those cells, and detecting the presence of a marker in the cellular composition that is not present in non-neuronal cells, the marker present in the cellular composition that is not present in the non-neuronal cells being a marker of neuronal cells. Thus, markers of the cellular composition can be compared to markers of non-neuronal cells to identify markers present in neurons, exclusively or in greater proportions. The neuron-specific markers can be useful in diagnostic and therapeutic techniques for neuronal diseases.

Additionally, the present invention provides a method of detecting a neuronally expressed gene comprising obtaining a cDNA library from the herein described cellular composition (which composition comprises greater than about 90%, preferably greater than about 95%, and more preferably greater than about 98%, mammalian, non-tumor-derived neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells), obtaining a cDNA

library from a non-neuronal cell, determining the presence at higher levels of a cDNA in the library from the cellular composition than in the non-neuronal cell, the presence at higher levels of a cDNA in the library from the cellular composition indicating a neuronally expressed gene. Thus, cDNA libraries derived from the neuronal
5 composition can be compared to a cDNA library from non-neuronal cells to identify genes expressed exclusively or in greater proportions in neuronal cells. Methods of performing such comparative screenings are known in the art, and thus can be readily performed by the artisan given the teachings herein. The neuron-specific markers could be useful in diagnostic and therapeutic techniques for neuronal diseases.

10

Utility of the Invention

Because mammalian neurons are generally incapable of dividing when mature, sources of dividing neuronal cells have been sought. The present invention provides a source of such dividing cells. These cells additionally demonstrate characteristics of
15 neuronal cells. Therefore, the cellular composition provides a useful composition for, for example, transplanting healthy cells having a neuronal phenotype into subjects whose neurons are degenerating or are not producing normal cellular molecules. The transplanted cells can then provide the deficient molecule(s) to the brain. For example, the present composition can be particularly useful for treating Parkinson's disease (PD),
20 which is characterized by a reduction in catecholamines, by transplanting the inventive cellular composition into the brains of subjects having PD. The transplanted cells can then provide catecholamines to the brain. Another example in which the present composition can be useful is in treating Huntington's Disease or in forms of epilepsy characterized by a reduction in GABA, because these cells can provide GABA to a brain
25 into which they are transplanted. Furthermore, the composition can be useful in providing the desired product of any nucleic acid into the central nervous system. Any desired nucleic acid can be transfected into the neuronal progenitor cells of the composition and transplanted into the central nervous system. An example of a disease that can be treated by such a method is Alzheimer's disease (AD). Cells having a nucleic
30 acid encoding, for example, a growth factor or a neurotrophic factor, can be injected into the brains of AD patients to decrease or prevent degeneration in the brain.

The present compositions additionally can be used to screen for markers of neuronal cells and can be used to further characterize and identify new neuronal cells. The markers can be used for example to detect or treat disease conditions or to identify the anterior portion of the subventricular zone in mammals. Such cells can also be
5 utilized to screen for compounds that affect neuronal cells, either positively or adversely. In this manner, compounds (e.g. novel growth factors) for treating neuronal disorders can be screened, and compounds harmful to neurons can be determined. Many other uses in diagnosis and treatment of neuronal diseases will be apparent to the artisan. The invention can be utilized in therapeutic treatment of any neuronal disease or disorder in
10 which the provision of a healthy neuron and/or a neuron expressing a desirable gene can alleviate some effects of the disease or disorder. Thus, it can have widespread uses, as will be apparent to the skilled artisan given the teachings herein.

The cells can also be used to produce neuronal growth factors for therapy or use as research tools in cell differentiation. The cells themselves can also be used as a
15 research tool to study cell growth and differentiation.

The present invention is more particularly described in the following Examples which are intended as illustrative only since numerous modifications and variations therein will be apparent to those skilled in the art.

20 EXAMPLES

Example 1

Microdissection and dissociation of SVZa cells: A method was devised to microdissect the SVZa from parasagittal sections of the newborn rat brain. To harvest SVZa cells,
25 P0-P1 Sprague-Dawley pups were anesthetized on ice, decapitated and their heads placed in cold sterile Ham's F-10 medium (Sigma). After removing the skull, the brain was placed in fresh medium and bisected at the midline. Under the dissecting microscope approximately 2 mm thick parasagittal sections were taken from the midline of the hemispheres and the SVZa microdissected as illustrated in Figure 1. The SVZa is
30 the dorsolateral portion of the anterior-most extent of the region surrounding the ventricles. It is anterior and dorsal to the striatum. The SVZa can be distinguished from

the surrounding structures by its position relative to the ventricle as well as by its coloration and texture. SVZa is white and more opaque than the overlying corpus callosum because it is so cell dense relative to the corpus callosum. The SVZa also appears more dense and uneven because of the cell density. In the neonatal rat, the SVZa can be found at approximately 2.0 mm anterior to bregma, 1.0 mm lateral to the
5 midline and 2.0 mm deep to the pial surface.

Pieces of SVZa tissue from several (7-15) pups were pooled in a sterile test tube containing approximately 5 ml of Hank's balanced salt solution (HBSS). The pieces
10 were incubated for 20 min at 37° C in a 0.1% trypsin and 0.01% DNase in HBSS and washed with medium containing 0.04% DNase in HBSS. The last wash volume was brought up to 5 µl per dissected tissue piece, resulting in 10⁵-10⁶ cells/ml. To achieve relatively even dissociation into single cells and small clumps, the tissue was thoroughly triturated.

15 Before transplantation or culture, cell viability was determined using the fluorescent FDA/PI (fluorescein diacetate/propidium iodide) method providing positive identification of living (green) and dead (red) cells. A viability of 80-95% has been routinely obtained from the freshly prepared cell suspensions.

20 **Example 2**

Cell labelling *in vitro*: In order to visualize cells transplanted into a host brain, the cells can be labelled with the lipophilic membrane bound dye, PKH26, which fluoresces red with a 551 nm excitation and 567 nm emission, can be used to label the dissociated SVZa cells immediately prior to transplantation. For the SVZa cells, the freshly
25 dissociated cell suspension was labelled with PKH26 (4 µM dye in diluent C, Sigma) for 3-5 min. Virtually all cells become intensely labeled.

In some experiments, BrdU (5 mg BrdU/ml of 0.007 N NaOH in 0.9% NaCl), a cell proliferation marker, has been used to label dissociated SVZa cells prior to transplantation. Using this labelling method, dividing cells can be visualized after
30 transplantation according to the procedure described by Menezes and Luskin, *J. Neurosci.* 14:5399 (1994). Specifically, bromo-deoxyuridine (BrdU) was added to the

- culture media, and then 1 to 24 hours later the cultures were fixed as described above and stained with antibodies to BrdU to reveal the presence of labeled cells. After fixation, the cultures were washed with 0.01 M PBS and treated with 2N HCl at 60°C to fragment the DNA followed by acid neutralization in 0.01 M borate buffer, pH 8.3.
- 5 After a thorough wash with PBS and application of blocking serum (10% normal goat serum with 0.01% Triton X-100 in 0.01 M PBS), the cultures were incubated overnight with a monoclonal antibody to BrdU (α -BrdU, Accurate, NY), at 4°C using a 1:500 dilution. Afterwards the cultures were rinsed with 0.1 M PBS and incubated with a rhodamine conjugated goat anti-rat secondary antibody (Jackson ImmunoResearch, PA)
- 10 at a 1:200 dilution for 1 hour at room temperature, washed in 0.1 M PBS and coverslipped using Vectashield (Vector, CA). BrdU-positive cells display a red fluorescent nucleus.

Example 3

- 15 Cell culture: The isolated SVZa cells in culture are essentially all neuronal, i.e., they are immunoreactive when stained with neuron-specific markers. To ascertain the phenotype of the harvested and dissociated SVZa cells, they were plated on uncoated glass microscope slides or poly-D-lysine or polyornithine coated glass slides and cultured in either full strength Ham's F10 medium (Sigma) or Dulbecco's minimal essential medium
- 20 DMEM (Sigma) supplemented with 10% fetal calf serum or 1:1 ratio of Ham's F10 medium:DMEM, at 37°C in 7% CO₂. Specifically, following dissociation, the cells were centrifuged at 700 rpm for 7 min, the pellet redispersed in new medium and the number of cells estimated using a hemacytometer. Approximately 3.32×10^3 cells were added to each well of the glass chamber slides (LabTek 16 well). Alternatively, cells
- 25 were plated at a density of 3.3 or 5.9×10^5 cells/cm². Each well was coated with 10 µg/ml of poly-D-lysine (P-7280, Sigma) for 1 h at 37°C in the incubator, rinsed 3 times with distilled water and air dried in the culture hood. Alternatively, the cells were plated on 10 µg/ml of mouse laminin (23017-015, Gibco), on 500 µg/ml poly-L-ornithine (P-3655, Sigma) or on a combination of both.
- 30 One to eight days later the SVZa cultures were fixed for 20 min in 4% paraformaldehyde and 0.12 M sucrose in 0.1 M PBS, rinsed in cold PBS, permeabilized

with 100% ethanol, rehydrated in an ethanol series and rinsed in PBS. After incubation in 50 mM glycine and three rinses in cold PBS, blocking serum (0.5% normal goat serum and 0.01% Triton X-100 in 0.1 M PBS) was applied for 1 hour. Cells were incubated overnight with a 1:500 dilution of the mouse monoclonal antibody TuJ1, a
5 neuron-specific antibody recognizing class III β -tubulin (Lee *et al.*, *Proc. Natl. Acad. Sci.* 87:7195 (1990)); supplied by Dr. A. Frankfurter, University of Virginia, Charlottesville, VA) and a rabbit polyclonal antibody (GFAP; Dako) to glial fibrillary acidic protein (Bignami *et al.*, *Brain Res.* 43:429 (1972)) at a dilution of 1:500. Cells were then rinsed in 0.1 M PBS and incubated for an hour in a mixture of secondary
10 antibodies including fluorescein goat anti-mouse (Jackson, 1:100) and rhodamine goat anti-rabbit (Jackson, 1:200), washed in 0.1 M PBS, pH 7.4, coverslipped using Vectashield (Vector, CA) and examined by epifluorescence microscopy.

To ascertain definitively the identity of the microdissected cells prior to transplantation, cells were plated and stained for cell-type specific markers to
15 characterize them. Characterizing the identity of the cells was done to determine the purity of the dissected cells and whether the microdissected cells contained progenitors for glia. As described above, the viability of the dissociated cells prior to plating was quite high; between 80-95 per cent and often higher than 95%. When viewed by bright-field and phase microscopy within the first few hours after plating, the vast majority of
20 cells adhered to the surface of the glass and some even extended one or two processes from their cell bodies. This indicates that some of the cultured cells began to differentiate almost immediately after plating. TuJ1, an antibody that recognizes neuron-specific class III β -tubulin (Lee *et al.*, *Proc. Natl. Acad. Sci.* 87:7195 (1990)), was used to identify cells with a neuronal phenotype and an antibody to GFAP to distinguish
25 astrocytes, a cell type commonly derived from other regions of the neonatal subventricular zone (Privat, *Int. Rev. Cytol.* 40:281 (1975); Levison and Goldman, *Neuron* 10:201 (1993); Luskin and McDermott, *Glia* 11:211 (1994)).

After one day *in vitro* (1 DIV) all or nearly all of the cultured SVZa cells stained with TuJ1. When viewed by bright-field and phase microscopy within the first few
30 hours after plating, the vast majority of cells adhered to the surface of the glass slide and

some even extended one or two processes from their cell bodies. This indicates that some of the plated cells began to differentiate almost immediately after plating.

After 24 hours in culture, the majority of the cultured cells either occurred in small
5 clusters containing 2-4 cells or as individual cells with a bipolar or occasionally
multipolar morphology. Interestingly, the overwhelming majority of clustered and
individual cells exhibited distinct TuJ1 immunoreactivity, apparent in the somatic
cytoplasm and cell processes. At this stage, GFAP-positive cells in the cultures were
rarely seen. The result showed that the plated cells possess a pronounced neuronal
10 identity. This result also indicated that only the SVZa was included in the dissection. If
this were not the case, GFAP-positive cells would be expected.

Cells were also stained at intermediate times up to 8 days in culture to discern
what proportion of the cells exhibit exclusively a neuronal phenotype. At 8 days, the
cultured cells occurred in small clumps or were loosely arranged and that the cells now
15 extended numerous intermingling processes. Again, nearly all of the cells expressed
prominent TuJ1 immunoreactivity. As in the short-term cultures, glia, as signified by
GFAP-immunoreactivity, represented less than 5% of all cultured cells. These findings
demonstrated that the region of the SVZa which contains a seemingly pure population
of neuronal progenitor cells can be isolated.

20 Since many types of neurons exhibit substrate-dependent process outgrowth, the
ability of SVZa-derived cells to extend processes was tested on different substrates.
SVZa cells were found to extend processes on poly-D-lysine at 10 µg/ml and on poly-L-
ornithine (or on poly-D-L-ornithine) and exhibited monopolar, bipolar and multipolar
morphologies. However, in contrast to cerebellar granule neurons, on 10 µg/ml laminin,
25 SVZa cells did not sprout.

Another unexpected property of the cultured SVZa cells is that they proliferate in
culture. This was surprising because most cells expressing neuron-specific cell markers
are post-mitotic cells (Moody *et al.*, *J. Comp. Neurol.* 279:567 (1989); Menezes and
Luskin, *J. Neurosci.* 14:5399 (1994). Furthermore, it is often difficult to establish
30 conditions under which cells giving rise to neurons can divide in culture, especially when
plated at low density, as in the present example. (Reynolds and Weiss, *Science*

255:1707 (1992). Not only did the cultured SVZa cells divide immediately after plating, but they also divided several days after they have been cultured.

To demonstrate that cultured SVZa cells undergo division, the cell proliferation marker bromo-deoxyuridine (BrdU) was added to the culture media, and then 1 to 24
5 hours later the cultures were fixed as described above and stained with antibodies to BrdU to reveal the presence of labeled cells. After fixation, the cultures were washed with 0.01 M PBS and treated with 2N HCl at 60°C to fragment the DNA followed by acid neutralization in 0.01 M borate buffer, pH 8.3. After a thorough wash with PBS and application of blocking serum (10% normal goat serum with 0.01% Triton X-100 in
10 0.01 M PBS), the cultures were incubated overnight with a monoclonal antibody to BrdU (α -BrdU, Accurate, NY), at 4°C using a 1:500 dilution. Afterwards the cultures were rinsed with 0.1 M PBS and incubated with a rhodamine conjugated goat anti-rat secondary antibody (Jackson ImmunoResearch, PA) at a 1:200 dilution for 1 hour at room temperature, washed in 0.1 M PBS and coverslipped using Vectashield (Vector,
15 CA). BrdU-positive cells display a red fluorescent nucleus.

Example 4

Homotopic transplantation of SVZa cells: To investigate the migratory behavior of homotopically transplanted SVZa-derived cells, dissociated donor rat SVZa cells were
20 implanted in the neonatal SVZa of a rat host. The purpose of the experiment was to determine if transplanted cells are able to read the same guidance cues and attain the same laminar distribution in the host brain as unmanipulated SVZa-derived cells. Dissociated SVZa cells rather than explants of tissue were transplanted to facilitate the integration of the transplanted cells in the host brain.

25 In order to analyze the migratory behavior of homotopically transplanted SVZa cells, the distribution of transplanted cells at 3 postimplantation time periods was examined: short survivals (after 1 week or less), intermediate survivals (after 2 to 3 weeks) and long survivals (4 weeks or longer). The experiment was performed to find out if the distribution of the transplanted cells matched that of the unmanipulated cells at
30 the various time points chosen for study. From our *in vivo* studies in which PKH26 was directly injected into the SVZa to label its cells, the time periods chosen for analysis

correspond to when SVZa-derived cells would occur predominantly in the pathway, subependymal zone of the olfactory bulb and overlying granule cell layer, and when they are in their final positions in the granule cell and glomerular layers.

5 Short-term survival

To compare the overall distribution and dynamics of cell movement by unmanipulated SVZa-derived cells to that of transplanted SVZa cells, dissociated PKH26-labeled SVZa cells were injected into the host SVZa. To visualize PKH26 labelled cells *in vivo*, animals were perfused with 4 % paraformaldehyde, their brains
10 removed, and sectioned on a Vibratome. Serial 100 µm sections were mounted and examined by fluorescence microscopy for PKH26-labeled cells. The subsequent position and morphology of the cells were examined within one week after transplantation.

Examination of host brains 1 day after transplantation revealed that the injection
15 site was usually centered in the SVZa and that it usually contained a high density of PKH26-labeled cells. At the injection site the red fluorescing PKH26-labeled cells were small and round. These cells usually occurred as individual cells or in small clumps, resembling freshly dissociated cells.

The path of migration demonstrated by transplanted SVZa cells matches precisely
20 the path followed by unmanipulated SVZa-derived cells. It constitutes a long pathway connecting the SVZa to the center of the olfactory bulb measuring several millimeters. At progressively longer times after transplantation the distribution of labeled cells extended further from the site of implantation.

By two days after transplantation, a continuous stream of cells was observed
25 coming from the rostral wall of the anterior horn of the lateral ventricle (SVZa) to the vertical limb of the pathway. By four days after transplantation the labeled cells were in the horizontal arm of the pathway, and some cells reached the central part of the olfactory bulb. At the end of the first week after transplantation, migrating cells were found evenly distributed throughout the subependymal layer extending from the SVZa
30 to the middle of the olfactory bulb. Moreover, as found for the unmanipulated SVZa-derived cells, the transplanted cells were strictly confined to the well-defined pathway

characterized by a region of high cell density. This demonstrates that the transplanted PKH26-labeled SVZa cells faithfully acknowledge the boundaries of the migratory pathway and do not deviate from it.

Fluorescence microscopy revealed that the majority of transplanted PKH26-labeled cells have a round soma, and that some have a relatively short and thick process extending toward the olfactory bulb. Within the subependymal zone of the olfactory bulb, many transplanted cells have an oval or spindle-shaped soma with a clear, unlabeled nucleus. In contrast to the unmanipulated SVZa-derived cells, at this stage only a low number of dye-labeled cells revealed processes. One possibility to account for the differential labeling of SVZa-derived cells is that perhaps the PKH26 does not label the transplanted cells in their entirety. Alternatively, perhaps some transplanted cells lack fully developed processes. In this case the transplanted cells may be able to reach the bulb by becoming incorporated into the stream of unmanipulated SVZa-derived cells which are also traveling to the olfactory bulb.

15

Intermediate survival

Distribution of transplanted cells in the migratory pathway and granule cell layer of the olfactory bulb. By two weeks after transplantation some of the transplanted cells had advanced into the granule cell layer of the olfactory bulb. It appeared as though the labeled cells had moved from the subependymal layer of the bulb into the overlying granule cell layer. Concomitantly, there was a striking reduction in the proportion of transplanted cells in the more caudal parts (vertical limbs) of the migratory pathway. By three weeks after transplantation a greater proportion the donor cells had entered the granule cell layer, leaving fewer in the subependymal zone and pathway distal to the olfactory bulb.

25

When the transplanted cells turned radially from the subependymal zone towards the granule cell layer, some of them began to differentiate into granule cells, revealing two PKH26-labeled processes. The transplanted cells within the granule cell layer, which presumably are undergoing differentiation, had the characteristic bipolar morphology of maturing, unmanipulated granule cells. The range of mature and immature morphologies seen among the PKH26-labeled cells 2-3 weeks after homotopic

30

transplantation indicates that the cells are at various stages of differentiation. In fact, some of the PKH26-labeled cells in the granule cell layer appeared to be still en route to the glomerular layer, judging by their spindle-shaped cell soma which is characteristic of migrating neurons.

- 5 In some experiments BrdU incorporation was used to label SVZa cells before transplantation. BrdU-labeled cells were visualized according to the procedure described by Menezes and Luskin *J. Neurosci* 14:5399 (1994). In brief, brains were perfused with 4% paraformaldehyde and then cryoprotected overnight in 20% sucrose in 0.1 M phosphate buffered saline (PBS). The brains were embedded in Tissue Tek
- 10 O.C.T. Compound, sagittally sectioned on a cryostat at 18 - 20 μ m and mounted on slides before processing for the presence of BrdU. The sections were washed with 0.01 M PBS and treated with 2N HCl at 60°C to fragment the DNA followed by acid neutralization in 0.01 M borate buffer, pH 8.3. After a thorough wash with PBS and application of blocking serum (10% normal goat serum with 0.01% Triton X-100 in
- 15 0.01 M PBS), the sections were incubated overnight with a monoclonal antibody to BrdU (α -BrdU, Accurate, NY), at 4°C using a 1:500 dilution. Afterwards the sections were rinsed with 0.1 M PBS and incubated with a rhodamine conjugated goat anti-rat secondary antibody (Jackson ImmunoResearch, PA) at a 1:200 dilution for 1 hour at room temperature, washed in 0.1 M PBS and coverslipped using Vectashield (Vector,
- 20 CA). BrdU-positive cells display a red fluorescent nucleus. The distribution of transplanted BrdU-labeled cells matched the distribution of PKH26-labeled cells when examined after the same survival period. Two weeks after transplantation, fluorescence microscopy revealed the presence of intensely labeled BrdU-positive cells predominantly in the portion of the migratory pathway close to the olfactory bulb (horizontal limb) and
- 25 in the subependymal zone of the bulb, although a few had advanced into the overlying granule cell layer. Thus, even though the BrdU labeling does not reveal the precise morphology of the transplanted cells, it clearly reveals their position.

Long-term survival

- 30 Both PKH26 and BrdU labeling procedures were used to unequivocally identify the transplanted SVZa-derived cells. In particular, there were concerns that over time

the PKH26 dye intensity may diminish. Therefore, most conclusions were based on the analysis of BrdU-labeled cells.

Previous studies showed that four weeks after an injection of retrovirus into the SVZa that the SVZa-derived cells have achieved their final laminar distribution (Luskin, *Neuron* 11:173 (1993)). In these experiments, a similar laminar distribution of transplanted cells was found. When compared with the intermediate survival, significantly higher numbers of transplanted cells were distributed throughout the granule cell layer. Another group of cells, most likely periglomerular cells, were found encircling the glomeruli. A few transplanted cells still occupied the rostral half of the subependymal layer of the olfactory bulb 4 weeks after transplantation. Thus, the sequential changes in the migratory pattern of unmanipulated SVZa cells seems to be matched by the homotopically transplanted cells. This suggests that they are able to discern the same set of guidance cues.

Quantitative analyses showed that the ratio between labeled cells in the glomerular layer and granule cell layer after transplantation was identical to what occurs in the unmanipulated brain (Luskin, *Neuron* 11:173, (1993)). Seventy-five percent of the transplanted cells ended up in the granule cell layer or adjacent to it and the other twenty-five percent were found in the glomerular layer of the olfactory bulb. Collectively, these findings suggest that transplanted SVZa-derived cells are not only able to adopt the same migratory route as their counterparts originating from the host SVZa but that they are also able to acquire the same laminar distribution between the granule cell and glomerular layers in the olfactory bulb.

Example 5

Heterotopic transplantation of SVZa cells into neonatal cerebellum, ventricular zone of embryonic telencephalon, or areas adjacent to the anterior portion of the subventricular zone: To make injections into the external granular layer of the neonatal cerebellum, a small incision through the skull overlying the midbrain and the hindbrain can be made and labeled SVZa cells can be injected using a Hamilton syringe into a position just beneath the meninges (Gao and Hatten, *Science* 260:367 (1993)).

To make injections into the ventricular zone of the embryonic telencephalon the procedure described by Dunnett and Bjorklund in *Transplantation: Neural Transplantation-A Practical Approach*, Oxford Univ. Press, Oxford (1992), can be followed. In brief, under deep anesthesia the abdominal wall of a pregnant dam can be
5 incised. The uterine horns can be exposed and each fetus transilluminated with the fiberoptic tube. A pipette containing labeled SVZa cells can be inserted through the uterine wall, amniotic sac, and the fetal skull into the ventricular zone overlying the cerebral cortex.

To investigate the behavior and distribution of SVZa cells transplanted into areas
10 adjacent to the anterior portion of the subventricular zone, SVZa cells were transplanted into position lying either posterior or lateral to the SVZa of the host. Retrovirus injections had shown that only when the injections were within the SVZa did the labeled cells end up in the olfactory bulb and become neurons (Luskin, *Neuron* 11:173 (1993), Luskin and McDermott, *Glia* 11:211 (1994)). Of the four animals used in this
15 experiment, no labeled cells were found in the migratory pathway or in the olfactory bulb following the nonSVZa injections, confirming that SVZa provides certain positional information to guide SVZa-derived cells to the olfactory bulb.

The phenotypic identity of unmanipulated SVZa-derived cells in the mature (> 6 weeks) olfactory bulb has been analyzed. The phenotype of SVZa-derived cells can be
20 classified according to their morphology (Pinching and Powell, *J. Cell Sci.* 9:305, 347, 379 (1971)) and the neurotransmitter candidates they contain (Bartolomei and Greer, *Neurosci. Abst.* 19:125 (1993). Halasz *et al. Brain Res.* 167:221 (1979) has shown that essentially all granule cells contain GABA, as do many periglomerular cells.

Periglomerular cells are also known to express tyrosine hydroxylase, the rate limiting
25 step in the synthesis of dopamine (McLean and Shipley, *J. Neurosci.* 8:3658 (1988). Moreover, Gall *et al. J. Comp. Neurol.* 266:307 (1987), and Kosaka *et al. Brain Res.* 343:166 (1985) have independently shown the colocalization of GABA and TH in subsets of periglomerular cells. Furthermore, since Celio *Neurosci.* 35:375 (1990), Halasz *et al. Neurosci. Letters* 61:103 (1985) and Kosaka *et al. Brain Res.* 411:373
30 (1987) reported that virtually all periglomerular cells are immunoreactive for calbindin (28K-vitamin-D-dependent calcium binding protein), calbindin immunoreactivity can be

determined in unmanipulated and transplanted BrdU-labeled SVZa cells situated in the glomerular layer express calbindin. Furthermore, the phenotype acquired by heterotopically transplanted SVZa-derived cells in the cerebellum and cerebral cortex, and that acquired by ventricular zone and EGL cells in the olfactory bulb can be
5 examined.

Example 6

Double-labeling: Following transplantation of BrdU-labeled SVZa cells into the SVZa, as described above, procedures have been devised to reveal the presence of BrdU and
10 transmitter candidates or their synthetic enzymes using double label procedures on 20 μ m cryostat sections. Following perfusion with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) brains were removed, equilibrated in 20 - 30 % sucrose in 0.1 M phosphate buffer overnight and then cut sagittally or coronally at a thickness of 20 μ m on a cryostat. Sections were washed in 0.1 M PBS, treated with 2N HCl at 45 -
15 50°C for 15 minutes and subsequently rinsed with 0.1 M borate buffer, pH 8.3 for 15 minutes. Sections were then incubated in 10% normal goat serum in PBS for 30 minutes and then overnight in a mixture of primary antibodies including anti-BrdU (1:500; Accurate, NY) and an antibody to either GABA (1:500; Sigma), TH (1:1000, Eugene Tech, NJ) or calbindin (Sigma, 1:1000 dilution). The next day the sections were
20 rinsed in 0.1 M PBS and incubated for 2 hours in an appropriate mixture of secondary antibodies that contain goat anti-rat IgG conjugated to rhodamine to visualize BrdU immunoreactive cells and FITC conjugated secondaries to identify one of the neurotransmitter candidates. Lastly the sections were rinsed in 0.1 M PBS and coverslipped.

25 Sections were examined with fluorescence microscopy to identify labeled SVZa cells, and their neurotransmitter phenotype and laminar position determined. The SVZa-labeled cells were evident by their red fluorescence and the transmitter labeling, when present in the same cells by green fluorescence of both unmanipulated and transplanted cells. The percentage of SVZa-derived GABAergic and TH-immunoreactive cells were
30 determined for unmanipulated cells in each layer of the olfactory bulb.

Previous studies have shown that the SVZa-derived cells are neurons based on their morphological features and laminar distribution. To further characterize the SVZa-derived neurons in the olfactory bulb, cell-type specific markers for transmitter phenotype were used. At P20, when most of the SVZa-derived cells have reached their final destination following an SVZa injection of BrdU at P2, BrdU-labeled cells were localized using immunohistochemistry and their neurotransmitter phenotype was assessed using antibodies against gamma-aminobutyric acid (GABA) and the dopamine synthesizing enzyme tyrosine hydroxylase (TH). Using simultaneous indirect immunofluorescence to detect the presence of single- and double-labeled cells, 10% of the SVZa-derived cells were found to be both BrdU- and TH-positive in the glomerular layer and that approximately 67% and 46% of the SVZa-derived cells in the granule cell layer and glomerular layer were GABAergic (GABA- and BrdU-positive), respectively. When analyzed at P20, 28% and 12 % of the periglomerular cells, that arose from a P2 injection of BrdU were TH- and GABA-positive respectively, were found. Similarly, at P20, 11% of the GABAergic neurons in the granule cell layer were generated on P2. These results indicate that the neonatal SVZa is a source of dopaminergic cells destined for the glomerular layer and also a source of GABAergic cells for the granule cell and glomerular layers.

The transmitter phenotype of unmanipulated SVZa-derived cells in the olfactory bulb can now be compared with the transmitter phenotype expressed by homotopically and heterotopically transplanted cells that reach the olfactory bulb after implantation in the SVZa. This can allow determination of whether transplanted cells acquire the same transmitter identity as unmanipulated SVZa-derived cells, or if transmitter candidates expressed by the heterotopically transplanted cells are more representative of the transmitters they ordinarily express. If the heterotopically transplanted cells reach the periglomerular layer and express TH, then conclusions can be drawn that their identity has been respecified; dopamine is ordinarily expressed only by cells of the substantia nigra and olfactory bulb. The phenotype of unmanipulated cells can be compared to the homotopically and/or heterotopically transplanted cells, *i.e.*, those implanted in the striatum.

Example 7

Heterotopic transplantation of cortical and cerebellar cells into neonatal SVZa: In additional experiments, it was investigated whether newly-generated neurons, which usually migrate along radial glia, could navigate the highly restricted path adhered to by SVZa derived cells that appears not to be guided by radial glia. Cerebellar external granule layer (EGL) cells (postnatal) and ventricular zone (VZ) cells (prenatal) were harvested for transplantation. In brief, EGL cells were removed by suction on the surface of the cerebellum or by microdissection and then trypsin and DNase were used to dissociate the cells as described above. To harvest progenitor cells of the E16 VZ, a modified procedure used by McConnell, *Brain Res. Rev.* 13:1 (1988), was employed. Dissociated cells from the VZ of the embryonic day 15 to 17 rat telencephalon or from the EGL of the postnatal day 5 (P5) or P6 cerebellum, were labeled with either the cell proliferation marker BrdU or the fluorescent lipophilic dye PKH26 and stereotactically implanted into the SVZa of P0-P2 rats. Results showed that heterotopically engrafted VZ cells remained at the site of infection. In contrast, heterotopically transplanted EGL cells traversed the migratory pathway, although most did not migrate away from the middle of the olfactory bulb (OB).

Example 8

Heterotopic transplantation of SVZa cells into the striatum: To maximize the number of labeled SVZa cells obtained for transplantation, P0-P1 donor pups were given 2-3 intraperitoneal injections (6 hours apart) of a BrdU stock solution (5 mg BrdU/ml of 0.007 N NaOH in 0.9% saline; 0.3 ml/pup/injection). The last injection was given one hour before dissection of the donor tissue.

The SVZa cells were dissected and dissociated as described above and the viability of the cell suspension determined as described above. A viability of about 80-95% was obtained, and the cell concentration ranged from 2.9×10^4 to 5.4×10^6 cells/ml. The dissociated cells were labeled with PKH26 by incubating the freshly prepared cell suspension in a 4.0 μ M solution of PKH26 dye and diluent C for 3-5 minutes according to the protocol provided by Sigma.

The dissociated and labeled SVZa cells were transplanted into the striatum of P0-P2 pups that were anesthetized by hypothermia. To reduce movement and maximize the consistency of injection coordinates, the head of the pup was placed on a Sylgard contoured mold. (To determine the coordinates for targeting the P0-P2 striatum, PKH26 was directly injected into the brains of four P0-P1 pups. The range of coordinates were chosen by comparing the results obtained from PKH26 injections as well as from a few initial transplantation experiments using implantation of labeled SVZa cells.) The injections were made between 0.8 - 2.0 mm anterior to bregma (A-P) and 1.2 - 2.3 mm lateral to the sagittal sinus (M-L) and 2.3 - 3.5 mm deep to the pial surface (depth). We demonstrated that injections within the following range of coordinates A-P, 1.0 - 1.5 mm; M-L, 1.8 - 2.3 mm and depth, 2.5 - 3.5 mm, were most likely to target the striatum (Table 1) and were in agreement with those used by Abrous et al. (1).

An incision was made through the skin overlying the sagittal suture to expose the skull. A small hole was made through the skull centered around 1.8-2.3 mm lateral to the sagittal suture and 1.0-1.5 mm anterior to the bregma. A 10 μ l Hamilton syringe, containing the SVZa cells, attached to a micromanipulator, was lowered approximately 2.5-3.5 mm from the pial surface and 2-4 μ l of the labeled cell suspension was injected into the striatum. Following transplantation, the overlying skin was repositioned and sealed with surgical glue and the pup was placed under a heat lamp for recovery before transferring it back to its home cage. Following transplantation the pups were allowed to survive for various time periods before they were perfused. At the time of perfusion the pups were anesthetized with ether and perfused transcardially with 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4). The brains were removed, blocked in the sagittal plane, and post-fixed in the same fixative for at least 1 h before washing with 0.1 M PBS. The BrdU and PKH26-labeled cells were detected as described above.

Table 1: Coordinates for implantation of SVZa cells and their subsequent distribution

30	Rat #	Age at implantation	Survival (days)	AP	Injection site (mm)		Amount injected (μ L)	PKH26 or BrdU	Labeled cells: in striatum/along striatal boundary
					M-L	Depth			
A. Short-term survival									
	1	P1	3	0.9	1.8	3.1	4	BrdU	+/-
	2	P1	5	0.8	1.7	2.4	3	PKH26	-/-

32

5	3	P1	2	0.7	2.0	3.1	3	BrdU	+/-
	4	P1	2	1.1	2.0	3.2	3	BrdU	+/-
	5	P1	2	1.0	2.2	3.2	3	BrdU	+/-
	6	P1	2	1.0	2.3	3.3	3	BrdU	+/-
	7	P1	2	0.8	2.0	3.2	3	BrdU	+/-
	8	P1	2	1.0	2.0	3.2	3	BrdU	+/-

B. Long-term survival

I. SVZa cells restricted to the striatum

10	1	P0	13	1.5	2.0	2.9	4	PKH26	
	2	P1	26	1.0	2.0	3.2	4	PKH26	
	3	P1	26	1.0	2.0	2.9	4	BrdU	
	4	P1	26	0.8	1.2	3.3	4	BrdU	

II. SVZa cells restricted to the striatal boundary

15	5	P1	13	2.0	1.7	2.3	2	PKH26	
	6	P0	20	1.2	2.0	2.5	2	PKH26	
	7	P1	28	1.2	1.5	3.3	3	BrdU	

III. SVAz cells within the striatum and along the striatal boundary

20	8	P2	13	1.0	2.0	3.3	3	BrdU	
	9	P1	18	1.2	2.0	3.3	4	BrdU	
	10	P0	26	1.0	2.0	3.0	4	PKH26	
	11	P1	26	1.0	2.0	3.0	4	PKH26	
	12	P1	41	1.2	2.0	3.4	4	BrdU	

IV. SVZa cells present elsewhere in the brain

25	13	P2	13	1.0	2.0	3.2	3	BrdU	
	14	P2	13	1.0	2.0	3.2	3	BrdU	
	15	P1	19	1.0	1.7	2.5	4	PKH26	
	16	P1	20	2.0	1.5	3.1	4	PKH26	
	17	P1	21	1.8	1.2	3.2	4	PKH26	

- 30 The brains of neonatal rat pups received transplants of labeled SVZa cells into the striatum and the ensuing distribution of the transplanted SVZa cells at the time of perfusion (Survival) was mapped. P0-P2 pups were implanted with PKH26- or BrdU-labeled P0-P2 SVZa cells. All the transplants were placed in the right hemisphere while the head was in the Sylgard mold. The reference points for the injection site coordinates were as follows: measured distance anterior to the bregma for the anteriorposterior (A-P) dimension, distance lateral to the sagittal sinus for the mediallylateral (M-L) dimension, and distance below the pial surface for the Depth. The presence or absence of labeled cells in the striatum or along the striatal boundary was scored as (+) or (-), respectively. A total of 25 brains were studied. They were grouped into short-term survival (2-5 days; $n=8$) and long-term survival (>13 days; $n=17$). Of the 17 brains in the long-term survival group, 12 brains were used for detailed analysis. In the remaining five brains the transplant was placed superficial to the striatum and was excluded from further consideration. Note that the distribution of the SVZa cells is not related to (1) the amount of cell suspension injected, (2) age of the host at the time of transplantation, or (3) survival time posttransplantation. Also, the presence of transplanted cells along the lateral cortical stream is not correlated with any particular set of coordinates.

Appearance of cells at injection site

Three days after transplanting SVZa cells into P1 striatum BrdU-labeled SVZa cells were readily identified in the middle of the striatum and in some cases also along the injection tract running through the corpus callosum. The presence of labeled cells
5 along the injection tract is probably due to the backflow of the cell suspension or because of a small amount of leakage of the labeled cells during insertion or withdrawal of the Hamilton syringe. The results show complete and heavy staining of the nuclei of the labeled cells soon after transplantation. Many of the BrdU-labeled cells were aggregated near blood vessels. In addition, at this short survival time cells were usually
10 seen adjacent to each other, although a few cells were more dispersed within the striatum and had evidently undergone migration.

Patterns of migration of donor SVZa cells in the host striatum

The unmanipulated SVZa cells generated between P0-P2 migrate several
15 millimeters to the subependymal layer in the middle of the olfactory bulb. By 4 weeks they attain their final position in the granule cell or glomerular layers. The distribution of the labeled SVZa cells in the host striatum was therefore examined at 2 to 4 weeks (long-term survivals, $n=17$, Table 1) after transplantation to investigate whether the SVZa cells had dispersed from their site of injection. We restricted our analysis to 12 of
20 the 17 injected brains in which SVZa transplants were located in the striatum. The remaining five brains were excluded from further consideration because we concluded that the SVZa cells were not implanted deep enough in the brain. The transplanted cells in these brains were found in the subventricular zone or corpus callosum dorsal to the ventricle overlying the striatum.

25 We observed three patterns of distribution of transplanted SVZa cells and thus grouped the results from the 12 brains accordingly: 1) cases in which the labeled cells were confined to the striatum; 2) cases in which the labeled cells were situated along the striatal boundary between the striatum and the corpus callosum; and 3) cases in which the labeled cells were present in both of the above-mentioned locations (Table 1). We
30 observed that the distribution of the SVZa cells was not related to the post-transplantation survival time, nor to the age of the host at the time of transplantation. A

striking finding of this study was that the injection site could not be demarcated 2-4 weeks post-transplantation in any of the cases studied; gliosis was not observed around the transplants. In addition, although SVZa cells were seen along the striatal boundary, they were never seen to cross it and migrate into the surrounding cerebral cortex.

5

Appearance and distribution of SVZa cells restricted to striatum.

The labeled SVZa cells were identified in the striatum in 4 out of 12 animals (Table 1) analyzed. In each brain the SVZa cells within the striatum occurred as individual cells or in small groups of usually no more than 2-4 cells. Large, closely
10 packed aggregates of cells were never observed 2-4 weeks after transplantation, indicating that the cells had migrated away from each other. The labeled cells were frequently found in close proximity to blood vessels. Although the labeled cells were present through the striatum, in the majority of the brains analyzed the labeled SVZa cells were situated closer to the lateral ventricle than to the lateral edge of the striatum.

15 Amongst the transplanted cells labeled with PKH26, small clumps of 2-4 cells were seen extending processes into the striatum. The BrdU-labeled SVZa cells located in the striatum 2-4 weeks following transplantation were not heavily stained as cells examined 3 days post transplantation. This suggested that the SVZa cells had undergone cell division after transplantation into the striatum. Our observations indicate
20 that the heterotopically transplanted SVZa cells retained their capacity to concurrently divide and migrate.

Unlike other studies in which cells were transplanted into the striatum, glial cells were rarely seen associated with the transplants. The presence of glial cells, a sign that the host striatum is reacting to the local trauma produced by the implantation procedure,
25 was absent in the SVZa transplants and could be attributed to the younger age of the donor and host animals used. The absence of the glial barrier could be partially responsible for the dispersion of the transplanted SVZa cells within the striatum. A possible reason the SVZa cells did not provoke an immune rejection by the host tissue could be because the SVZa cells used for transplantation were a substantially
30 homogeneous population of neuronal progenitor cells. Neurons do not have antigen presenting capability and thus are not able to initiate an immune response. Glial cells,

the early targets in a rejection process, are generally absent from the transplanted SVZa cell suspension.

Appearance and distribution of SVZa cells restricted to the striatal boundary.

5 Even though similar coordinates were used for implantation in all the animals, the distribution of transplanted SVZa cells varied. In some cases (3 out of 12) following transplantation, the PKH26- or BrdU-labeled cells were identified only along the striatal boundary adjacent to the corpus callosum and not within the striatum proper (Table 1). Labeled SVZa cells were present along the dorsal, lateral and ventro-lateral aspects of
10 the striatal boundary 2-4 weeks after implantation. The outlining of the contour of the striatum by labeled cells suggests that they had arrived at their position by migration, rather than being placed at the borders of the striatum simply as a result of the injection. Various intensities of BrdU staining was observed among the labeled SVZa cells, which were observed either individually or in small groups. The PKH26-labeled cells seen
15 along the striatal boundary did not appear to have any prominent morphological features; they were often round without any processes similar to other individual cells. This indicates that the cells at the border of the striatum may not undergo differentiation as they do when situated in the striatum.

20 *Appearance and distribution of SVZa cells within the striatum and along the striatal boundary.*

In 5 out of the 12 animals labeled cells were seen both within the striatum and along the striatal boundary (Table 1) 2-4 weeks following transplantation. Also various intensities of BrdU staining were observed amongst the labeled cells. In the majority of
25 the cases the SVZa cells located within the striatum, were in closer proximity to the striatal boundary and labeled SVZa cells were distributed all along the striatal edge between the striatum and the corpus callosum as described previously.

The relationship of the transplanted SVZa cells to the lateral cortical stream.

30 Of significance is the fact that in 8 of the 12 animals (67%) the SVZa cells were present along the striatal boundary. This region along the striatal boundary corresponds

to the lateral cortical stream of migration described by Bayer and Altman in *Neocortical Development*, New York:Raven Press, Ltd., pp. 116-127 (1991) which is present prenatally and is used by ventricular zone-derived cells of the developing cortex to reach the lateral and ventro-lateral cortical plate. The presence of transplanted SVZa cells distributed along this curved pathway, suggests that the SVZa cells are able to decipher guidance cues, used by other migrating cells.

Short Term Survival of Transplanted Neonatal Subventricular Zone Progenitor Cells.

The short-term behavior and phenotype of dissociated, BrdU-labeled SVZa cells transplanted stereotactically into the striatum of adult rats was examined. Three days after transplantation most SVZa cells were immunoreactive for TuJ1, an antibody which recognizes neuron-specific class III β -tubulin. Within the adult striatum only the transplanted SVZa cells stained intensely for TuJ1. Three days after transplantation, TuJ1(+) cells were also identified within 50 - 250 μ m of the transplant, suggesting that these cells had migrated from their site of implantation. Within two weeks, transplanted cells had dispersed up to 600 μ m. A very small number of the transplanted cells were GFAP(+). However, the transplant contained numerous GABA(+) cells. Some of the transplanted cells, within the first couple of weeks of transplantation, were tyrosine hydroxylase positive, as determined by antibody staining. Thus, SVZa cells have the capability to disperse and differentiate into neurons following transplantation into an adult striatum.

Example 9

Transfection of neuronal progenitor cells: Cells were harvested from the SVZa, dissociated, and plated in 16 well chamber slides in Ham's F10 medium with 1% penicillin/streptomycin and 10% fetal calf serum. Between 3×10^4 and 8×10^4 cells per well were added. Either the next day or several hours later, the cells were infected with retrovirus (either BAG, which expresses β gal in the cytoplasm at 1.04×10^6 particles/ml, or nls-lacZ retroviral vector, which expresses β gal in the nucleus [gift of Dr. Gary Nolan; *Proc. Natl. Acad. Sci. USA* 84:6795-6799 (1987)]], at 1.54×10^6 particles/ml) in varying amounts (30 μ l-200 μ l) and 0.6 μ l/well of a 1 mg/ml solution of

polybrene was added. Cells were fixed a day later with 2% paraformaldehyde, 0.4% glutaraldehyde, 0.1 M PBS. The X-Gal incubation mixture (Luskin, *Neuron* 11:173 (1993)) was added and the number of blue cells/total cells in each dish was determined. Up to 4 % of the cells were blue, indicating they had been transfected or had inherited
5 the transfected gene.

Example 10

Generation of immortalized clonal cell lines from the SVZa: Primary cultures can be made at low density from dissociated SVZa from newborn rats. These cultures can then
10 be transfected with a retrovirus containing both the temperature sensitive SV40 Large T and neo^r genes. After the infection, G418 (a neomycin analog) can be added to the growth medium in order to select for cells that have integrated the retrovirus thus acquiring neomycin resistance. G418 selection can be maintained until colonies form on the dishes. After these colonies form, each can be isolated and expanded in separate
15 dishes to produce sublines hopefully consisting of mitotic clones of a single infected primary cell.

Southern analysis can be used to verify or disprove the clonality of each subline. It is important to establish clonal cell lines due to the random nature of retroviral integration which may affect expression of the immortalizing Large T antigen. The
20 SV40 Large T antigen cDNA can be used to probe several different restriction digests of genomic DNA isolated from each cell line. This can allow analysis of each subline for the length of the integrated construct, number of integration sites, and the clonal relationships between each line.

At the same time, each subline can be expanded in culture to demonstrate the
25 ability to passage *in vitro*. As soon as enough cells are available, each subline can be frozen in order to preserve samples early in their immortalized life span.

To obtain cells from the SVZa, newborn (P0) Sprague-Dawley rat pups anesthetized by hypothermia can be decapitated, and the brains can be dissected into ice-cold Ca²⁺/Mg²⁺ free HBBS. After removal of meninges, the anterior portion of the
30 subventricular zone can be dissected under the microscope (Figure 1). This tissue can then be incubated in 0.15% trypsin in Eagle's Basal Medium for 20 minutes. Following

this incubation, the tissue can undergo aspiration with a fire-polished Pasteur pipette to generate a single cell suspension. Cells can then be plated at a low density in 1:1 DMEM:HAMS media supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin onto several poly-D-lysine coated 35 mm plastic culture dishes.

- 5 The cells can be grown at 39°C for 24 hours.

Twenty-four hours after plating the primary SVZa cultures, the cells can be moved to 33°C, and the media can be replaced with the supernatant from the producer cell line containing the replication defective retrovirus encoding the ts SV40 Large T antigen. 8 µg/ml polybrene can also be added to the cultures to facilitate retroviral entry into the
10 cells. After 4 hours, the retroviral supernatant can be replaced with fresh DMEM/HAMS medium, and the cells can be kept at 33°C. The following day, 0.5 mg/ml G418, a neomycin analog, can be added to the media in order to select for neomycin resistant cells. This selection media can be changed every 3-5 days. As colonies form on the dishes, they can be isolated with cloning rings and transferred to
15 separate wells in a 24 well plate. Each subline can then be expanded and passaged to provide cells for study. A subset of each line can also be frozen in 10% DMSO in medium.

High molecular weight genomic DNA can be prepared from each cell line as previously described (Maniatis et al., *Molecular Cloning (A Laboratory Manual)*, Cold
20 Spring Harbor, Cold Spring Laboratories, 1982). 10 µg of DNA can be cut with XbaI, EcoRI, and BglIII in separate reactions. XbaI cuts at both ends of the retroviral insert while both EcoRI and BglIII cut only once within the construct. Then, the DNA can be size fractionated on 0.8% agarose gels alongside DNA markers of known size and transferred to a nylon filter (GeneScreen Plus, Dupont) as described by Southern, 1975.
25 The filterbound DNA can then be hybridized to a random primed SV40 Large T antigen probe under stringent conditions.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention
30 pertains.

Although the present process has been described with reference to specific details of certain embodiments thereof, it is not intended that such details should be regarded as limitations upon the scope of the invention except as and to the extent that they are included in the accompanying claims.

What is claimed is:

1. An isolated cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells.
2. The composition of Claim 1, wherein greater than about 95% of the mammalian, non tumor-derived, neuronal progenitor cells express a neuronal marker and can give rise to progeny which can differentiate into neuronal cells.
3. The composition of Claim 1, wherein the isolated neuronal progenitor cells can, without being first immortalized, divide for at least two generations.
4. The composition of Claim 1, wherein the neuronal progenitor cells are rat cells.
5. The composition of Claim 1, wherein the neuronal progenitor cells are human cells.
6. The composition of Claim 1, wherein at least a portion of the population of neuronal progenitor cells, or their progeny, is transfected with an exogenous nucleic acid.
7. The composition of Claim 6, wherein the exogenous nucleic acid functionally encodes a biologically active molecule.
8. The composition of Claim 7, wherein the exogenous nucleic acid functionally encodes a biologically active molecule that stimulates cell division or differentiation.

9. The composition of Claim 7, wherein the exogenous nucleic acid functionally encodes a biologically active molecule that functions in the synthesis of a neurotransmitter.
10. A method of delivering a biologically active molecule produced by the neuronal progenitor cells of the cellular composition of Claim 1, or their progeny, or mixtures thereof, to a region of a mammalian brain comprising transplanting the cellular composition of Claim 1 into the region of the brain, thereby delivering a biologically active molecule produced by the cells or their progeny to the region.
11. A method of delivering a biologically active molecule produced by the neuronal progenitor cells of the cellular composition of Claim 7, or their progeny, or mixtures thereof, to a region of a mammalian brain comprising transplanting the cellular composition of Claim 7 into the region of the brain, thereby delivering the biologically active molecule produced by the cells or their progeny to the region.
12. A method of treating a neuronal disorder characterized by a reduction of catecholamines in the brain of a mammal, comprising transplanting into the brain the cellular composition of Claim 1, or their progeny, or mixtures thereof, thereby providing a source of catecholamines to the brain and treating the disorder.
13. The method of Claim 12, wherein the neuronal disorder is Parkinson's disease.
14. A method of treating Alzheimer's disease in a subject comprising transplanting into the brain of the subject the cellular composition of Claim 8, or their progeny, or mixtures thereof, thereby treating Alzheimer's disease.
15. A method of treating Alzheimer's disease in a subject comprising transplanting into the brain of the subject the cellular composition of Claim 9, or their progeny, or mixtures thereof, thereby treating Alzheimer's disease.

16. A method of treating a neuronal disorder characterized by a reduction of γ -aminobutyric acid in the brain in a mammal, comprising transplanting into the brain the cellular composition of Claim 1, or their progeny, or mixtures thereof, thereby providing a source of γ -aminobutyric acid to the brain and treating the disorder.

17. The method of Claim 16, wherein the neuronal disorder is Huntington's Disease.


18. A method of screening for a marker of neuronal cells comprising obtaining the neuronal progenitor cells of Claim 1, and detecting the presence of a marker in the neuronal progenitor cells that is not present in non-neuronal cells, the marker present in the neuronal progenitor cells that is not present in the non-neuronal cells being a marker of neuronal cells.

19. A method of detecting a neuronally expressed gene comprising obtaining a cDNA library from the neuronal progenitor cells of Claim 1, obtaining a cDNA library from a non-neuronal cell, determining the presence at higher levels of a cDNA in the library from the neuronal progenitor cells than in the non-neuronal cell, the presence at higher levels of a cDNA in the library from the neuronal progenitor cells indicating a neuronally expressed gene.

20. A method of obtaining an isolated cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuronal marker and which can give rise to progeny which can differentiate into neuronal cells, comprising isolating cells from the portion of a mammalian brain that is the equivalent of the anterior portion of the subventricular zone at the dorsolateral portion of the anterior-most extent of the region surrounding the ventricle of a neonatal rat brain and culturing the isolated cells in the absence of mitotic inhibitors.

21. An isolated cellular composition comprising greater than about 50% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which give rise to progeny which can differentiate into neuronal cells.

1/2



DISSECTION

FIG.1A




DISSOCIATION

FIG.1B



LABELING


FIG.1C



TRANSPLANTATION

FIG.1D

2/2



DISSECTION

FIG. 2A




DISSOCIATION

FIG. 2B



LABELING

FIG. 2C



TRANSPLANTATION

FIG. 2D

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/11304

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 48/00; C12N 5/00; C12Q 1/02, 1/68

US CL :435/6, 29, 240.1; 424/93.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 29, 240.1; 424/93.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CHEMICAL ABSTRACTS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	REYNOLDS, B. A. et al. Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System. Science. 27 March 1992, Vol. 255, pages 1707-1710, especially page 1708.	1-9, 20 and 21
Y	US 5,082,670 A (F. GAGE ET AL) 21 January 1992, column 2, line 32 to column 3, line 25 and column 23, line 30 to column 26, line 3.	10-17
Y	VAYSSE, P. J.-J. et al. A Clonal Analysis of Glial Lineages in Neonatal Forebrain Development In Vitro. Neuron. September 1990, Vol. 5, pages 227-235, especially page 228 and 229.	18



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

T

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

A

document defining the general state of the art which is not considered to be of particular relevance

X

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

E

earlier document published on or after the international filing date

Y

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

L

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O

document referring to an oral disclosure, use, exhibition or other means

&

document member of the same patent family

P

document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

19 SEPTEMBER 1996

Date of mailing of the international search report

02 OCT 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DEBORAH CROUCH

Telephone No. (703) 308-0196

US 095818900IP1



Creation date: 28-08-2003
Indexing Officer: FNIGATU - FITSUM NIGATU
Team: OIPEBackFileIndexing
Dossier: 09581890

Legal Date: 05-10-2000

No.	Doccode	Number of pages
1	M903	1

Total number of pages: 1

Remarks:

Order of re-scan issued on